Kazuhiko Nakagawa
#126,186
Most Influential Person Now
Researcher ORCID ID = 0000-0003-1284-9776
Kazuhiko Nakagawa's AcademicInfluence.com Rankings
Kazuhiko Nakagawacomputer-science Degrees
Computer Science
#5311
World Rank
#5610
Historical Rank
Machine Learning
#1361
World Rank
#1382
Historical Rank
Artificial Intelligence
#1596
World Rank
#1626
Historical Rank
Database
#2467
World Rank
#2584
Historical Rank
Download Badge
Computer Science
Kazuhiko Nakagawa's Degrees
- PhD Computer Science University of Tokyo
- Masters Computer Science University of Tokyo
- Bachelors Computer Science University of Tokyo
Similar Degrees You Can Earn
Why Is Kazuhiko Nakagawa Influential?
(Suggest an Edit or Addition)Kazuhiko Nakagawa's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. (2010) (3811)
- Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. (2013) (3079)
- Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. (2003) (2937)
- First-line crizotinib versus chemotherapy in ALK-positive lung cancer. (2014) (2577)
- Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). (2011) (1443)
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. (2020) (873)
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. (2017) (693)
- Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial (2017) (650)
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer (2017) (646)
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. (2014) (645)
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab (2011) (577)
- CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. (2013) (542)
- CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. (2018) (406)
- Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. (2016) (372)
- Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. (2008) (359)
- Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). (2006) (354)
- Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. (2015) (342)
- Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. (2018) (336)
- Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. (2008) (335)
- Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer (2020) (323)
- Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (309)
- Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. (2003) (271)
- Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. (2011) (262)
- Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. (2010) (232)
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies (2020) (215)
- Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. (2016) (204)
- Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines. (1990) (197)
- Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. (2018) (191)
- Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival (2017) (189)
- Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. (1990) (177)
- Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). (2004) (177)
- Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. (2012) (175)
- The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC (2017) (170)
- FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. (2010) (167)
- Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors (2009) (166)
- Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab (2017) (164)
- Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer (2011) (162)
- Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). (2010) (159)
- Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). (2012) (159)
- Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. (2010) (159)
- Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. (2021) (158)
- Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. (2007) (157)
- Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT) (2019) (156)
- Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients (2008) (152)
- Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. (2015) (149)
- CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. (1992) (148)
- Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non–Small Cell Lung Cancer Cell Lines (2008) (144)
- Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer (2012) (141)
- Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer (2011) (131)
- Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. (2016) (130)
- Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. (2016) (129)
- MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations (2011) (129)
- Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. (2017) (119)
- Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer (2008) (112)
- The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer (2013) (112)
- Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer (2017) (110)
- Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. (2016) (110)
- Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. (2007) (109)
- Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification (2011) (107)
- Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. (2016) (104)
- First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014) (2014) (103)
- Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. (1990) (102)
- Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status (2008) (102)
- Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection (2014) (102)
- Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014 (2018) (98)
- Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. (1994) (98)
- Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. (1995) (98)
- Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer (2014) (96)
- Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. (2019) (95)
- Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L. (2015) (94)
- Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. (2020) (94)
- Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer (2020) (92)
- Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors (2010) (91)
- Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. (2014) (90)
- MET amplification as a potential therapeutic target in gastric cancer (2012) (89)
- DS‐8201a, a new HER2‐targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2‐positive gastric cancer T‐DM1 resistance (2017) (89)
- B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity (2018) (88)
- Targeting MET Amplification as a New Oncogenic Driver (2014) (88)
- A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer (2008) (88)
- First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer? (2019) (86)
- LEVELS OF GLUTATHIONES TRANSFERASE π mRNA IN HUMAN LUNG CANCER CELL LINES CORRELATE WITH THE RESISTANCE TO CISPLATIN AND CARBOPLATIN (1988) (86)
- A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study) (2016) (85)
- Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. (2010) (84)
- Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset (2018) (83)
- EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. (2006) (83)
- TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation (2010) (82)
- Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. (1991) (81)
- Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin (2006) (81)
- Pharmacokinetics of (glycolato-0,0′)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin (2004) (80)
- Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor (2010) (79)
- Enhanced Antitumor Efficacy of a Combination of CPT‐11, a New Derivative of Camptothecin, and Cisplatin against Human Lung Tumor Xenografts (1993) (79)
- Dual EGFR/VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. (2020) (78)
- Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II Study (2008) (78)
- Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors (2009) (77)
- Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification (2012) (76)
- Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. (1995) (76)
- Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site. (2019) (74)
- Combination therapy with PD-1 or PD-L1 inhibitors for cancer (2019) (73)
- The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. (1999) (73)
- Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor (2021) (72)
- Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. (2012) (72)
- Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy. (2019) (71)
- Clinical Impact of Continued Crizotinib Administration after Isolated Central Nervous System Progression in Patients with Lung Cancer Positive for ALK Rearrangement (2013) (71)
- Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib (2016) (71)
- A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. (2015) (71)
- Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs (2010) (70)
- Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Non–Small-Cell Lung Cancer (NSCLC): An Interim Analysis of 3488 Patients (POLARSTAR) (2012) (70)
- Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. (2006) (70)
- Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification (2011) (70)
- SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion (2009) (70)
- De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer (2010) (70)
- Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. (2014) (69)
- In vitro antitumor activity of mitomycin C derivative (RM-49) and new anticancer antibiotics (FK973) against lung cancer cell lines determined by tetrazolium dye (MTT) assay (2004) (69)
- Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase (2008) (69)
- Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. (1994) (68)
- Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. (2019) (68)
- A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors (2016) (67)
- Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer. (2013) (67)
- Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib‐resistant non‐small cell lung cancer cells with acquired MET amplification (2010) (67)
- Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. (2015) (67)
- A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. (2016) (67)
- Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. (1995) (66)
- Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary (2015) (66)
- Detection of the T790M mutation of EGFR in plasma of advanced non–small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study) (2016) (65)
- Overcoming Erlotinib Resistance in EGFR Mutation–Positive Non–Small Cell Lung Cancer Cells by Targeting Survivin (2011) (65)
- Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression. (2016) (65)
- Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP (2017) (65)
- Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. (2004) (63)
- Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041) (2017) (63)
- Results of a randomized phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small cell lung cancer who failed one or two chemotherapy regimens (2007) (63)
- Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. (2010) (62)
- Establishment and characterization of cisplatin‐resistant sublines of human lung cancer cell lines (1988) (60)
- Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. (1992) (60)
- Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer (2017) (59)
- The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells (2014) (59)
- Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer (2014) (59)
- Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells (2009) (58)
- Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. (2011) (57)
- A phase I study of GW572016 in patients with solid tumors. (2004) (57)
- In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. (1989) (56)
- Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients (2016) (56)
- Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation–Positive Non–Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib (2014) (55)
- Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. (2018) (54)
- Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial. (2014) (54)
- Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. (2018) (54)
- An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC (2018) (54)
- Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer (2011) (52)
- A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours (2006) (52)
- Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells (2012) (52)
- Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure. (2011) (52)
- XAGE-1 Expression in Non–Small Cell Lung Cancer and Antibody Response in Patients (2005) (52)
- Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer (2017) (52)
- Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors (2016) (51)
- Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan. (2002) (51)
- Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with MET Amplification (2009) (51)
- Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer. (2013) (50)
- Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced non-squamous non-small cell lung cancer. (2021) (50)
- HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer (2015) (50)
- Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk (2007) (49)
- Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. (2006) (48)
- Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition (2010) (48)
- LBA2_PRGEFITINIB/CHEMOTHERAPY VS CHEMOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC) AFTER PROGRESSION ON FIRST-LINE GEFITINIB: THE PHASE III, RANDOMISED IMPRESS STUDY (2014) (48)
- Mutational analysis of the β-tubulin gene in lung cancer (2002) (47)
- Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition (2014) (46)
- [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification (2019) (44)
- NDRG1/Cap43/Drg-1 may Predict Tumor Angiogenesis and Poor Outcome in Patients with Lung Cancer (2012) (43)
- Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy: A Pooled Analysis on Asian versus Non-Asian in Phase II and III Clinical Trials (2011) (43)
- Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). (2014) (43)
- The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer (2015) (43)
- Inhibition of &bgr;-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation (2015) (43)
- Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer (2009) (42)
- Immunoscreening of a cDNA library from a lung cancer cell line using autologous patient serum: Identification of XAGE‐1b as a dominant antigen and its immunogenicity in lung adenocarcinoma (2004) (41)
- Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer. (2015) (41)
- Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing (2015) (39)
- Point mutations of the topoisomerase IIalpha gene in patients with small cell lung cancer treated with etoposide. (1996) (39)
- S-1 Plus Cisplatin with Concurrent Radiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Multi-Institutional Phase II Trial (West Japan Thoracic Oncology Group 3706) (2011) (39)
- Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer (2017) (39)
- Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non‐small cell lung cancer (2008) (38)
- Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma (2014) (38)
- Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin (1995) (38)
- Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial. (2017) (38)
- Synergistic Antitumor Effect of S-1 and HER2-Targeting Agents in Gastric Cancer with HER2 Amplification (2010) (38)
- Over‐Expression of the Testis‐Specific Gene TSGA10 in Cancers and Its Immunogenicity (2004) (37)
- Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial. (2020) (37)
- Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study. (2011) (37)
- Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. (2022) (37)
- Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib (2016) (36)
- HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer (2018) (36)
- Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy. (2013) (36)
- Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer (2019) (36)
- Histology and Smoking Status Predict Survival of Patients with Advanced Non–Small-Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study 3906L (2013) (36)
- Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer (2013) (36)
- Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. (2015) (35)
- High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin (2011) (34)
- SRPX2 Is a Novel Chondroitin Sulfate Proteoglycan That Is Overexpressed in Gastrointestinal Cancer (2012) (34)
- Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis (2020) (34)
- Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open‐label, randomized, phase 2 trial (2016) (34)
- Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib. (2016) (34)
- KEYNOTE‐025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1–positive advanced non–small‐cell lung cancer (2019) (34)
- Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405). (2013) (33)
- OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01 (2021) (33)
- Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. (2021) (33)
- Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity. (2010) (33)
- Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors (2014) (33)
- Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study (2014) (32)
- Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study (2018) (32)
- Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses (2007) (32)
- Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy. (1989) (32)
- Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment (2012) (32)
- Unusual variant of left paraduodenal hernia herniated into the mesocolic fossa leading to jejunal strangulation (1998) (32)
- Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. (2011) (32)
- Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non–Small-Cell Lung Cancer (2015) (32)
- A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. (2018) (32)
- Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors. (2007) (32)
- Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L) (2020) (31)
- Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. (2020) (31)
- Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. (2019) (31)
- Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells (2011) (31)
- Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer (2006) (31)
- Identification of thymidylate synthase as a potential therapeutic target for lung cancer (2010) (31)
- Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT) (2021) (31)
- Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations (2020) (31)
- FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib (2016) (31)
- Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002). (2007) (30)
- Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion. (2019) (30)
- Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancer. (2012) (30)
- Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin. (2012) (30)
- Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal. (2015) (30)
- U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. (2019) (29)
- ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in Japan. (2015) (29)
- A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. (2006) (29)
- The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations (2010) (28)
- Antitumor activity of a new platinum compound (glycolate-o,o') diammineplatinum (II) (254-S), against non-small cell lung carcinoma grown in a human tumor clonogenic assay system. (1988) (28)
- Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial. (2020) (28)
- Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer (2011) (28)
- RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC). (2019) (28)
- Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. (2019) (27)
- Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision‐Making for Patients with Advanced Solid Tumors (2020) (27)
- Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients. (2012) (27)
- Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma (2013) (27)
- A phase II study of topotecan in patients with relapsed small-cell lung cancer. (2003) (27)
- Subcutaneous Administration of Recombinant Human Granulocyte Colony‐stimulating Factor (KRN8601) in Intensive Chemotherapy for Patients with Advanced Lung Cancer (1990) (27)
- Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. (2012) (26)
- Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer. (2017) (25)
- A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer. (2014) (25)
- Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non–Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505 (2008) (24)
- A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L (2018) (24)
- Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience (2007) (24)
- Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer (2018) (24)
- A Multi-Institution Phase I/II Trial of Triweekly Regimen with S-1 Plus Cisplatin in Patients with Advanced Non-small Cell Lung Cancer (2010) (24)
- Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients. (2011) (24)
- Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors. (2008) (23)
- Sorting nexin 2‐mediated membrane trafficking of c‐Met contributes to sensitivity of molecular‐targeted drugs (2013) (23)
- Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease. (2010) (23)
- Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. (1989) (23)
- Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial. (2014) (23)
- An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors (2018) (23)
- Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset (2018) (22)
- Characterization of an etoposide-resistant human small-cell lung cancer cell line (2008) (22)
- Ritterazine B, a new cytotoxic natural compound, induces apoptosis in cancer cells (2003) (22)
- Brief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA. (2019) (22)
- Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. (2017) (22)
- LBA50Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK+ lung cancer: Updated results from PROFILE 1014 (2017) (22)
- KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms (2021) (22)
- Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan. (2019) (21)
- Cystic brain metastasis in non-small-cell lung cancer with ALK rearrangement. (2014) (21)
- A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutation: Final Overall Survival and Biomarker Analysis. (2019) (21)
- Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC). (2017) (21)
- Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin. (1990) (21)
- Prediction from Creatinine Clearance of Thrombocytopenia and Recommended Dose in Patients Receiving (Glycolato‐O, O′)‐diammine Platinum (II) (NSC 375101D) (1990) (21)
- Phase I study of dasatinib (BMS‐354825) in Japanese patients with solid tumors (2011) (21)
- Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement. (2012) (21)
- The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo (2007) (21)
- Significance of FGF9 gene in resistance to anti‐EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti‐EGFR therapies (2017) (21)
- A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: Updated safety and efficacy results from AF-001JP. (2013) (21)
- A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK+ NSCLC) patients (pts): Updates on progression free survival (PFS) and safety results from AF-001JP. (2015) (21)
- Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer (2017) (21)
- Regression of brain metastases from breast cancer with eribulin: a case report (2013) (20)
- Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group (2014) (20)
- Crizotinib for ALK rearrangement-positive non-small cell lung cancer patients with central nervous system metastasis (2016) (20)
- Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung cancer (NSCLC). (2015) (20)
- Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients. (2008) (20)
- Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts (2020) (20)
- The anti‐EGFR monoclonal antibody blocks cisplatin‐induced activation of EGFR signaling mediated by HB‐EGF (2008) (20)
- Clinical and immune profiling for cancer of unknown primary site (2019) (20)
- [Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib]. (2004) (20)
- Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer. (2011) (20)
- Mutational analysis of the beta-tubulin gene in lung cancer. (2002) (19)
- Chemoradiotherapy in Elderly Patients With Non–Small‐Cell Lung Cancer: Long‐Term Follow‐Up of a Randomized Trial (JCOG0301) (2018) (19)
- Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study. (2022) (19)
- A Novel Mass Spectrometry–Based Assay for Diagnosis of EML4-ALK–Positive Non–Small Cell Lung Cancer (2012) (19)
- Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2 (2018) (19)
- P-615 Phase II trials of gefitinib (‘Iressa’, ZD1839): rapid and durable objective responses in patients with advanced non-small-cell lung cancer (IDEAL 1 and IDEAl 2) (2003) (19)
- A Microarray-Based Gene Expression Analysis to Identify Diagnostic Biomarkers for Unknown Primary Cancer (2013) (19)
- Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer (2004) (19)
- Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors (2009) (19)
- Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II–IIIA Non–Small Cell Lung Cancer (2015) (19)
- Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG0401) (2010) (19)
- Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer (2014) (18)
- Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cells. (2007) (18)
- Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis. (2008) (18)
- A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer. (2005) (18)
- Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC). (2019) (18)
- A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors (2013) (18)
- Phase II study of carboplatin in small cell lung cancer. (1988) (18)
- Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer? (2006) (18)
- Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer. (1991) (18)
- Identification of glioma‐specific RFX4‐E and ‐F isoforms and humoral immune response in patients (2005) (18)
- Chemotherapeutic drugs that penetrate the blood–brain barrier affect the development of hyperactive delirium in cancer patients (2014) (18)
- Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. (2009) (18)
- Identification of an HLA‐A24‐Restricted OY‐TES‐1 Epitope Recognized by Cytotoxic T‐Cells (2005) (17)
- Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). (2019) (17)
- Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1 (2016) (17)
- Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). (2019) (17)
- Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients (2009) (17)
- Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer. (2017) (17)
- New Era for Next-Generation Sequencing in Japan (2019) (17)
- Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer. (2019) (17)
- Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies (2020) (17)
- A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer (2015) (17)
- Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B (2013) (16)
- Reversible posterior leukoencephalopathy syndrome and trastuzumab (2012) (16)
- Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan) (2004) (16)
- Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. (2017) (16)
- Left atrial extension of metastatic lung tumor via pulmonary vein: report on the first case of Ewing sarcoma (2010) (16)
- Safety and efficacy of first‐line dacomitinib in Japanese patients with advanced non‐small cell lung cancer (2020) (16)
- Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial. (2014) (16)
- Three Schedules of Recombinant Human Interleukin‐2 in the Treatment of Malignancy: Side Effects and Immunologic Effects in Relation to Serum Level (1988) (16)
- Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors (2012) (16)
- A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia. (2009) (16)
- Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non‐small‐cell lung cancer with or without prior crizotinib therapy (2016) (15)
- In vitro colony inhibition of carboplatin against stomach and lung cancer cell lines in comparison with cisplatin (2004) (15)
- Survivin inhibition by si-RNA induces apoptosis and increases sensitivity to adriamycin in human lung cancer cells with p53 mutation (2004) (15)
- Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR (2017) (15)
- A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non–small‐cell Lung Cancer Harboring EGFR Mutations (WJOG6911L) (2019) (15)
- T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non–Small Cell Lung Cancer (2017) (15)
- Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. (2019) (15)
- Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402. (2011) (15)
- Echinoderm microtubule‐associated protein‐like 4–anaplastic lymphoma kinase‐targeted therapy for advanced non‐small cell lung cancer: Molecular and clinical aspects (2012) (15)
- Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC. (2019) (15)
- Phase I trial of OTS11101, an anti‐angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor (2013) (14)
- XAGE‐1 mRNA Expression in Prostate Cancer and Antibody Response in Patients (2005) (14)
- Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer (2018) (14)
- RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer (2021) (14)
- Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer (2014) (14)
- A Randomized Phase II Study Comparing Nivolumab With Carboplatin‐Pemetrexed for Patients With EGFR Mutation–Positive Nonsquamous Non–Small‐Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Stud (2017) (14)
- Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer. (2013) (14)
- Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor (EGFR) activating mutation(s). (2013) (14)
- Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L). (2012) (14)
- Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T-cells. (2007) (14)
- HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer (2021) (13)
- A phase II study of osimertinib for radiotherapy-naïve CNS metastasis from non-small cell lung cancer: Results for the T790M cohort of the OCEAN study (LOGIK1603/WJOG9116L). (2021) (13)
- Quantitative real-time RT-PCR analysis of NY-ESO-1 and LAGE-1a mRNA expression in normal tissues and tumors, and correlation of the protein expression with the mRNA copy number. (2005) (13)
- Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset (2017) (13)
- Detection of the T 790 M mutation of EGFR in plasma of advanced non – small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors ( West Japan oncology group 8014 LTR study ) (2016) (13)
- Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer (2015) (13)
- Antitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study. (2014) (13)
- A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC) (2014) (13)
- Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines. (2007) (13)
- Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY (2020) (12)
- Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). (2021) (12)
- Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. (2020) (12)
- Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC. (2018) (12)
- Prospective replication study implicates the catechol-O-methyltransferase Val158Met polymorphism as a biomarker for the response to morphine in patients with cancer. (2017) (12)
- Clinical response to crizotinib retreatment after acquisition of drug resistance. (2013) (12)
- Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small Cell Lung Cancer (2012) (12)
- Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M–positive non–small cell lung cancer: West Japan Oncology Group 8815L/LPS study (2020) (12)
- In vitro growth inhibition of cisplatin-resistant human lung cancer cell lines by recombinant human tumor necrosis factor and/or recombinant human interferon-gamma by virtue of collateral sensitivity. (1987) (12)
- Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy (2017) (12)
- Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer. (2010) (12)
- Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer. (2015) (12)
- Prognostic Impact of Minimal Pericardial Effusion in Patients With Advanced Non–small‐cell Lung Cancer (2017) (12)
- Malignant pleural effusion from lung adenocarcinoma treated by gefitinib. (2011) (12)
- First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset (2020) (12)
- A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing (2019) (12)
- Large cell neuroendocrine carcinoma of the mediastinum with alpha-fetoprotein production. (2008) (12)
- Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L) (2012) (12)
- Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer (2006) (12)
- Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors using interim results of post-marketing all-case surveillance. (2017) (12)
- Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced non-small cell lung cancer with EGFR mutation; West Japan Oncology Group 6911L. (2021) (12)
- Phase II Study of Sequential Triplet Chemotherapy, Irinotecan and Cisplatin Followed by Amrubicin, in Patients with Extensive-Stage Small Cell Lung Cancer: West Japan Thoracic Oncology Group Study 0301 (2010) (12)
- Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment (2012) (11)
- Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study (2020) (11)
- Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy‐induced colitis (2021) (11)
- Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial. (2021) (11)
- Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis. (2018) (11)
- Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer (2020) (11)
- A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors (2015) (11)
- Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression. (2012) (11)
- LBA44 Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study (2021) (11)
- MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX) (2017) (11)
- Phase 2 study of S‐1 and carboplatin plus bevacizumab followed by maintenance S‐1 and bevacizumab for chemotherapy‐naive patients with advanced nonsquamous non–small cell lung cancer (2013) (11)
- Colony Inhibitory Effect of Recombinant Human Tumor Necrosis Factor (rH-TNF) and/or Recombinant Human Interferon (rH-IFN)-α -β and -γ on Human Lung Cancer Cell Lines (1987) (11)
- Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed (2010) (11)
- Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine (2017) (11)
- Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab (2017) (11)
- Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence (2014) (10)
- Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L (2021) (10)
- Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies (2019) (10)
- A multicenter prospective study of carboplatin and paclitaxel for advanced thymic carcinoma: West Japan Oncology Group 4207L. (2013) (10)
- Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget’s disease (2016) (10)
- Lentinula edodes mycelia extract plus adjuvant chemotherapy for breast cancer patients: Results of a randomized study on host quality of life and immune function improvement (2017) (10)
- P3-148: Evaluation of efficacy and safety of erlotinib as monotherapy for Japanese patients with advanced non–small cell lung cancer (NSCLC); integrated analysis of two Japanese phase II studies (2007) (10)
- Participation of poly(ADP-robose) polymerase in the drug sensitivity in human lung cancer cell lines (2005) (10)
- Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer (2020) (10)
- Randomized Phase II Study of Carboplatin-Paclitaxel or Gemcitabine-Vinorelbine in Patients With Advanced Nonsmall Cell Lung Cancer and a Performance Status of 2: West Japan Thoracic Oncology Group 0004 (2012) (10)
- Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer (2010) (10)
- Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis. (2019) (10)
- Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations (2018) (10)
- Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity (2016) (10)
- Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients. (2019) (10)
- Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial. (2015) (10)
- Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study) (2022) (10)
- A randomized double-blind phase IIa dose-finding study of ZD6474 in Japanese patients with NSCLC. (2006) (10)
- Phase II study of cisplatin, etoposide and concurrent thoracic radiotherapy (TRT) followed by irinotecan and cisplatin in patients with limited stage small-cell lung cancer (SCLC); updated results of WJTOG9902. (2004) (10)
- A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L) (2021) (9)
- Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double‐Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation‐Positive Metastatic Non–Small‐Cell Lung Cancer (2017) (9)
- Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer (2020) (9)
- Human epidermal growth factor eyedrops for cetuximab-related filamentary keratitis. (2011) (9)
- Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid (2017) (9)
- A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706. (2011) (9)
- A phase II study of nivolumab: a multicenter, open-label, single arm study in malignant pleural mesothelioma (MERIT). (2018) (9)
- Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG‐TR) (2020) (9)
- A first-in-human phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLC. (2012) (9)
- Inhibition of Colony Formation of Drug‐resistant Human Tumor Cell Lines by Combinations of Interleukin‐2‐activated Killer Cells and Antitumor Drugs (1989) (9)
- Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study) (2017) (9)
- Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors (2010) (9)
- [Novel signal transduction pathways: the molecular basis for targeted cancer therapies in Hedgehog/Notch/Wnt pathway]. (2015) (9)
- 9002 A phase III, first-line trial of gefitinib versus cisplatin plusdocetaxel for patients with advanced or recurrent non-small cell lungcancer (NSCLC) harboring activating mutation of the epidermal growthfactor receptor (EGFR) gene: a preliminary results of WJTOG 3405 (2009) (8)
- Genetic analysis of second primary lung cancers in patients surviving small cell lung cancer. (1996) (8)
- Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma. (2019) (8)
- A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients. (2006) (8)
- A randomized phase III study of cisplatin (CDDP), etoposide (ETOP) and irinotecan versus topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer (SCLC): Japan Clinical Oncology Group study JCOG0605 (2014) (8)
- Cytogenetic effect of carboplatin on human lymphocytes (2004) (8)
- Phase II Trial of 5‐Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer (2018) (8)
- EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use. (2022) (8)
- Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy (2020) (8)
- Randomized phase III study comparing carboplatin plus pemetrexed followed by pemetrexed versus docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L). (2019) (8)
- Safety and efficacy of nintedanib (BIBF 1120) plus pemetrexed in Japanese patients with advanced or recurrent non-small cell lung cancer (NSCLC): A phase I study. (2013) (8)
- Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L). (2019) (8)
- Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer (2015) (8)
- Clinical development of nintedanib for advanced non-small-cell lung cancer (2015) (8)
- Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC). (2021) (8)
- Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary? (2020) (7)
- Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study (2021) (7)
- Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI (2019) (7)
- Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study. (2021) (7)
- Guidance for ALK Gene Testing in Lung Cancer Patients (2012) (7)
- Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung (2013) (7)
- A randomized phase II study of TS-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC): WJOG 5008L. (2015) (7)
- Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L) (2020) (7)
- Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer. (2010) (7)
- O1-10-3Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer (2015) (7)
- [Tyrosine kinase inhibitors--solid cancers]. (2001) (7)
- Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer. (2018) (7)
- Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial (2022) (7)
- Real‐world safety of nivolumab in patients with non‐small‐cell lung cancer in Japan: Postmarketing surveillance (2021) (7)
- Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies (2020) (7)
- NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary. (2020) (7)
- Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease (2021) (7)
- Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non–small cell lung cancer (2012) (7)
- Lack of correlation between interferon levels induced by polyribonucleotides and their antimetastatic effect. (1990) (7)
- Treatment of EGFR mutation–positive non–small cell lung cancer complicated by Trousseau syndrome with gefitinib followed by osimertinib: a case report (2018) (7)
- Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study (2020) (7)
- Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR‐mutated non–small cell lung cancer (2019) (7)
- Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer (2021) (7)
- Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation. (2016) (7)
- Pemetrexed-induced edema of the eyelid. (2006) (7)
- Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer (2017) (7)
- Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients. (2010) (7)
- A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS. (2019) (7)
- Serial Measurement of Sister Chromatid Exchanges in the Peripheral Lymphocytes of Patients with Lung Cancer Receiving Chemotherapy in Relation to Bone Marrow Toxicity (1989) (7)
- Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis (2021) (7)
- Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer. (2015) (7)
- Clinical outcome of node‐negative oligometastatic non–small cell lung cancer (2016) (7)
- Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells. (2018) (6)
- Nivolumab + chemotherapy vs chemotherapy in EGFR-mutated NSCLC after 1L or 2L EGFR-TKIs (CheckMate 722) (2019) (6)
- A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancer. (2014) (6)
- Familial adenomatous polyposis complicated by chronic myelogenous leukemia: response to imatinib mesylate (2007) (6)
- Phase II study of erlotinib plus tivantinib in patients with EGFR-mutation–positive NSCLC who failed in immediately previous EGFR-TKI therapy. (2014) (6)
- First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset * (2021) (6)
- 1243 Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumors (2009) (6)
- A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib (2018) (6)
- MA11.03 Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01 (2021) (6)
- Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L). (2021) (6)
- First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer. (2019) (6)
- Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer (2021) (6)
- Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer (2015) (6)
- CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib (2021) (6)
- Molecular Cancer Therapeutics Identification of cSrc as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to cSrc Inhibition (2010) (6)
- Late toxicities and complications in three-year survivors of small cell lung cancer. (1991) (6)
- A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L) (2020) (6)
- A phase III study comparing amrubicin and cisplatin (AP) with irinotecan and cisplatin (IP) for the treatment of extended-stage small cell lung cancer (ED-SCLC): JCOG0509. (2012) (6)
- Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter (2014) (6)
- Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors (2019) (5)
- Negative phase II study of 5-fluorouracil with high-dose leucovorin in non-small cell lung cancer. (1990) (5)
- Docetaxel + ramucirumab (DR) versus docetaxel + placebo (D) as second-line treatment for advanced non-small cell lung cancer (NSCLC): A randomized, phase II, double-blind, multicenter trial in Japan. (2015) (5)
- Phase II study of carboplatin in non-small cell lung cancer. (1989) (5)
- Sterilized talc pleurodesis for malignant pleural effusions: a Phase II study for investigational new drug application in Japan (2018) (5)
- P2.06-002 Phase I Study of DS-6051b, a ROS1/NTRK Inhibitor, in Japanese Subjects with Advanced Solid Tumors Harboring Either a ROS1 or NTRK Fusion Gene: Topic: Phase I Trials (2017) (5)
- Phase 3 Clinical Trial for the Combination of Erlotinib plus Ramucirumab Compared with Osimertinib in Previously Untreated Advanced or Recurrent Non–Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L) (2021) (5)
- Redevelopment of Small‐Cell Lung Cancer Nine Years after the Start of Therapy A Case Report and Review of the Literature (1991) (5)
- 6560 POSTER Prognostic factors affecting survival on pretreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) – Subgroup analysis in a randomized Ph II study of pemetrexed 500 mg/m2 and 1000 mg/m2 (2007) (5)
- [Systemic chemotherapy for brain metastasis from small cell lung cancer]. (1993) (5)
- Colony inhibitory effect of recombinant human tumor necrosis factor (rH-TNF) and/or recombinant human interferon (rH-IFN)-alpha, -beta and -gamma on human lung cancer cell lines. (1987) (5)
- Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer? (2016) (5)
- Perirenal hematoma associated with bevacizumab treatment (2012) (5)
- Antitumor activity of quinocarmycin against carcinoma of the lung in human tumor clonogenic assay. (1987) (5)
- P-582 Dose-finding study of weekly irinotecan(CPT-11) and carboplatin (CBDCA) with concurrent thoracic radiotherapy(TRT) in locally advanced non-small cell lung cancer(NSCLC) (2003) (5)
- Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors in Japan. (2009) (4)
- Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB–IIIA non-small cell lung cancer (WJTOG0101) (2021) (4)
- Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14 (2020) (4)
- A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study) (2021) (4)
- Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT (2014) (4)
- Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb‐202 in gastric cancer (2021) (4)
- A Phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for Stage III non-small cell lung cancer: WJTOG 3305. (2012) (4)
- A Phase II Study of Nivolumab in Patients With Advanced Non–small‐cell Lung Cancer who Responded to Prior PD‐1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L) (2019) (4)
- Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection (2022) (4)
- A Phase I Study of Topotecan Plus Carboplatin for Relapsed SCLC: WJTOG Trial (2009) (4)
- Prognostic value of Lung Cancer Subscale in older patients with advanced non-small cell lung cancer: An integrated analysis of JCOG0207 and JCOG0803/WJOG4307L (JCOG1414A). (2018) (4)
- B3-01: A randomized Phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with previously treated advanced non-small-cell lung cancer (2007) (4)
- Oral S-1 and carboplatin plus bevacizumab with maintenance S-1 and bevacizumab for chemo-naive patients (Pts) with advanced non-squamous non-small cell lung cancer (NSCLC). (2012) (4)
- 486 A phase I study of pemetrexed supplemented with folic acid (FA) and vitamin b12 (VB12) in Japanese patients with solid tumors (2004) (4)
- Phase I and Pharmacokinetic Study of Combination Chemotherapy Using Irinotecan and Paclitaxel in Patients with Lung Cancer (2006) (4)
- Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer. (2021) (4)
- Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs. (2019) (4)
- Incidence of carnitine deficiency in patients with cancer pain: A pilot study (2017) (4)
- Administration of gefitinib via nasogastric tube effectively improved the performance status of a patient with lung adenocarcinoma-derived meningeal carcinomatosis (2014) (4)
- Gankyrin Contributes to Tumorigenesis and Chemoresistance in Sporadic Colorectal Cancer (2018) (4)
- The anti-HER 3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells (2015) (4)
- Pharmacokinetics of docetaxel in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis. (2012) (4)
- Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma (2021) (4)
- ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer (2018) (4)
- Differential roles of STAT 3 depending on the mechanism of STAT 3 activation in gastric cancer cells (2014) (4)
- Novel Drug Development of the Next-Generation T790M Mutant SpecificEpidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for theTreatment of Advanced Non-Small Cell Lung Cancer (2016) (4)
- Comparative study of the antitumor effect of two types of murine recombinant interferons, (beta) and (gamma), against B16-F10 melanoma. (1988) (4)
- Updated results of a phase III trial comparing standard thoracic radiotherapy (RT) with or without concurrent daily low-dose carboplatin in elderly patients (pts) with locally advanced non-small cell lung cancer (NSCLC): JCOG0301. (2012) (4)
- A randomized phase III study of continuous maintenance bevacizumab with or without pemetrexed after induction therapy with carboplatin (Car), pemetrexed (Pem), and bevacizumab (Bev) for advanced non-squamous non-small cell lung cancer (nSQ-NSCLC) without sensitizing EGFR mutations: The COMPASS study (2019) (4)
- Overcoming Erlotinib Resistance in EGFR Mutation-Positive Non-Small-Cell Lung Cancer Cells by Targeting Survivin (2012) (4)
- Brigatinib in Japanese patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): First results from the J-ALTA tyrosine kinase inhibitor (TKI)-naive expansion cohort. (2021) (3)
- Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. (2022) (3)
- Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC (2019) (3)
- Real-world safety of nivolumab in patients with non-small cell lung cancer (NSCLC) in Japan: Interim summary of post-marketing all-case surveillance. (2018) (3)
- Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial. (2021) (3)
- [Mechanisms of antibody-based therapy against solid tumors]. (2012) (3)
- P2-274: Clinical benefits of pemetrexed 500 mg/m2 and 1000 mg/m2 in a randomized phase II study for pretreated patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) (2007) (3)
- O1-9-2Phase I / II study of ASP8273 in patients with non-small-cell lung cancer (NSCLC) harboring EGFR activating mutations (2015) (3)
- Comparative studies of pulse and continuous exposure in human tumor clonogenic assay. (1987) (3)
- Soluble heregulin, HER3 ligand, to predict the efficacy of anti-HER3 antibody patritumab combination with erlotinib in randomized phase II study, HERALD, for non-small cell lung cancer. (2016) (3)
- The colony inhibition of a new chemotherapeutic agent (KW2152) against human lung cancer cell lines (2004) (3)
- Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L) (2021) (3)
- Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. (2022) (3)
- Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report. (2016) (3)
- Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer. (2020) (3)
- RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC). (2020) (3)
- An integrated analysis of comprehensive geriatric assessment (CGA) in elderly patients with non-small cell lung cancer (NSCLC) (JCOG1115-A). (2012) (3)
- Current status and future perspectives of cooperative study groups for lung cancer in Japan. (2014) (3)
- Estimation of whole-body radiation exposure from brachytherapy for oral cancer using a Monte Carlo simulation (2017) (3)
- RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability (2021) (3)
- Increased natural killer resistance to cyclosporine A by continuous doses of dexamethasone in rats (1997) (3)
- PS-1FIRST-LINE CRIZOTINIB VS PEMETREXED + CISPLATIN/CARBOPLATIN IN ASIAN PATIENTS WITH ADVANCED ALK+ NSCLC IN PROFILE 1014 (2014) (3)
- Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer (2015) (3)
- Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer. (2017) (3)
- A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer (2015) (3)
- Chemosensitivity test for human small cell lung cancer cell lines in vitro. (1986) (3)
- A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site (2013) (3)
- Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset (2021) (3)
- Randomized phase III study of nedaplatin (N) plus docetaxel (D) versus cisplatin (C) plus D for advanced or relapsed squamous cell carcinoma of the lung (SqLC): WJOG5208L. (2015) (3)
- Disturbance of the growth hormone-insulin-like growth factor-1 axis associated with poor performance status in patients with solid tumors. (2010) (3)
- Brigatinib in Japanese ALK positive NSCLC patients previously treated with ALK tyrosine kinase inhibitors: J-ALTA. (2020) (3)
- Primary results from Japanese phase I study of pembrolizumab plus chemotherapy as front-line therapy for advanced NSCLC (2019) (3)
- Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte‐ColONy Stimulating Factor Support for Elderly Patients With Advanced Non–small‐cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L) (2018) (3)
- Severe Immune-Related Hepatitis Treated With Plasma Exchange. (2020) (3)
- NDRG 1 / Cap 43 / Drg-1 may Predict Tumor Angiogenesis and Poor Outcome in Patients with Lung Cancer (2012) (2)
- Abstract 44: U3-1402, a novel HER3-targeting ADC, and a novel DNA topoisomerase I inhibitor inhibit the growth of non-small cell lung cancer with EGFR mutation (2017) (2)
- Phase II study of erlotinib plus tivantinib ( ARQ 197 ) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI , ge fi tinib or erlotinib (2016) (2)
- Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer. (2013) (2)
- The Efficacy and Safety of Sterile Graded Talc in Pleurodesis for Malignant Pleural Effusion: Phase II Study (2017) (2)
- Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation. (2016) (2)
- Phase II Study of 3-Week Scheduling of Irinotecan in Combination With Cisplatin in Patients With Advanced Nonsmall-Cell Lung Cancer (2006) (2)
- Epoetin Beta Subcutaneous Administration to Lung Cancer Patients with Anemia; Results of Pharmacokinetics/Pharmacodynamics Study (2007) (2)
- Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L). (2022) (2)
- Studies on the metabolism of three BSP fractions in patients with constitutional jaundice. (1985) (2)
- LBA45 Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC) (2021) (2)
- 未治療の非小細胞肺癌患者に対するゲフィチニブとカルボプラチン・パクリタキセルの第III相国際共同試験（IPASS）の全生存期間最終解析 (2012) (2)
- The Efficacy and Safety of Sterile Graded Talc in Pleurodesis for MalignantPleural Effusion: Phase II Study (2016) (2)
- Molecular Cancer Therapeutics Synergistic Antitumor Effect of S-1 and HER 2-Targeting Agents in Gastric Cancer with HER 2 Amplification (2010) (2)
- Evaluation of pembrolizumab monotherapy in patients with salivary gland carcinoma in the phase 2 KEYNOTE-158 study (2021) (2)
- A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study). (2019) (2)
- PS-3Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS > =50%, treatment-naïve NSCLC (2017) (2)
- Transient Effectiveness of an Oral 5-Fluorouracil Derivative, S-1, for Epirubicin, Cyclophosphamide and Paclitaxel Refractory Skin Metastases from Possible Occult Breast Cancer in a Male (2011) (2)
- The expression level of HER3 ligand heregulin mRNA as a predictive biomarker for anti-HER3 antibody patritumab combined with erlotinib in non-small cell lung cancer. (2014) (2)
- [Molecular targeted therapy in lung cancer]. (2010) (2)
- In vitro antitumor effect of recombinant human tumor necrotizing factor on cultured human cancer cell lines and freshly isolated lung cancer cells by the human tumor clonogenic assay (1987) (2)
- Abstract A241: Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells. (2013) (2)
- Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication (2021) (2)
- The difference in surface phenotypes between cytotoxic lymphocytes induced in vivo by systemic administration of human recombinant interleukin-2 and lymphokine activated killer cells induced in vitro. (1988) (2)
- Safety and Efficacy of Alectinib in a Patient With Advanced NSCLC Undergoing Hemodialysis. (2019) (2)
- Randomized trial of thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer (NSCLC): Long-term follow-up of Japan Clinical Oncology Group (JCOG) Study JCOG0301. (2017) (2)
- GALAXY-2 trial: A randomized phase III study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced non-small cell lung adenocarcinoma. (2013) (2)
- Correlative study of EGFR mutations or protein expressions of EGFR, phosphorylated EGFR, HER2, phosphorylated HER2 and IGFR-1 with gefitinib sensitivity in patients with non-small cell lung cancer: Results of West Japan Thoracic Oncology Group trial (WJTOG0203A): A5-03 (2007) (2)
- Phase I Clinical and Pharmacokinetic Study of RAD 001 ( Everolimus ) Administered Daily to Japanese Patients with Advanced Solid Tumors (2009) (2)
- Identification of DR 9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD 4 T-cells (2)
- Phase II Study of Nimotuzumab in Combination With Concurrent Chemoradiation Therapy (CRT) in Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC) (2012) (2)
- A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer (2013) (2)
- An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy (2018) (2)
- Comparative study of the antitumor effect of two types of murine recombinant interferons, (β) and (γ), against B16-F10 melanoma (2004) (2)
- Phase I study of sunitinib (SU) in combination with pemetrexed (Pem) in patients (pts) with advanced solid tumors (ST). (2009) (2)
- Abstract 4833: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutics antibody cetuximab (2012) (2)
- SY12-3Safety of crizotinib in 892 Japanese ALK-positive advanced NSCLC patients: Interim report of post-marketing surveillance (2015) (2)
- Gemcitabine-cisplatin (GC) + necitumumab (N) versus GC as first-line treatment for stage IV squamous cell lung cancer (SqCLC): An open-label randomized multicenter phase Ib-II trial in Japan. (2018) (2)
- Clinical Response to Everolimus of EGFR–Mutation‐Positive NSCLC With Primary Resistance to EGFR TKIs (2017) (2)
- O-219 Preliminary results of four arm cooperative study (FACS) for Advanced Non-Small Cell Lung Cancer (NSCLC) in Japan (2003) (2)
- A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L). (2021) (2)
- Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC). (2019) (2)
- Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L). (2019) (1)
- Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study (2020) (1)
- Phase I/II study of alectinib (CH5424802/RO5424802) in patients with alk-rearranged non-small cell lung cancer (NSCLC): Updated results from the AF-001JP trial (2014) (1)
- Phase I clinical and biomarker study of BIBF 1120, an oral multitarget tyrosine kinase inhibitor, in patients with advanced solid tumors (ST): Impact of CD133- and CD117-positive cells on a biomarker of an antiangiogenic inhibitor. (2009) (1)
- Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L) (2012) (1)
- 3325 Safety and efficacy of Pembrolizumab (MK-3475) for Japanese patients (pts) with advanced melanoma: Preliminary results from KEYNOTE-041 Phase 1b study (2015) (1)
- Phase III study of induction chemotherapy (docetaxel and carboplatin) with or without radiotherapy followed by surgery in patients with stage IIIA (pN2) non-small cell lung cancer (NSCLC): WJTOG9903. (2009) (1)
- Progression from early to advanced stage of immune‐related cholangitis (2022) (1)
- A Case of Pulmonary Tumor Thrombotic Microangiopathy Suggested by the Presence of Tumor Cells in Peripheral Blood (2020) (1)
- Long-term response to ipilimumab after nivolumab failure in a case of anorectal melanoma with an intermediate tumor mutation burden and negative for PD-L1 expression. (2020) (1)
- Preliminary analysis of the phase II study of pemetrexed plus carboplatin as first-line chemotherapy for elderly patients with advanced nonsquamous, non-small cell lung cancer. (2014) (1)
- RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non–Small-Cell Lung Cancer (NSCLC) (2022) (1)
- Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study) (2022) (1)
- Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer. (2020) (1)
- Multiplex genomic profiling of non-small cell lung cancer patients enrolled in the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin (WJOG6611LTR). (2014) (1)
- 811 Adjuvant therapy with gefitinib (‘Iressa’, ZD1839) following complete resection in Japanese patients with non-small-cell lung cancer: safety report of the first 38 patients recruited (2003) (1)
- P3.02b-073 A Phase II, Liquid Biopsy Study Using Digital PCR in EGFR Mutated, Lung Cancer Patients Treated with Afatinib (WJOG 8114LTR): Topic: EGFR Clinical (2017) (1)
- NGSCUP: Phase II trial of site-specific treatment based on gene expression and mutation profiling by next generation sequencing (NGS) for patients (pts) with cancer of unknown primary site (CUP). (2020) (1)
- Abstract 4657: MET amplification as a potential therapeutic target in gastric cancer. (2013) (1)
- Characterization and Mechanism of Resistance Cell Line of Human Non-Small Cell Lung Cancer : Establishment of a Camptothecin Analogue ( CPT-11 )-resistant (2006) (1)
- Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial (2021) (1)
- Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L) (2022) (1)
- Successful treatment with atezolizumab combination chemotherapy in a patient with high‐grade fetal adenocarcinoma of the lung: A case report (2022) (1)
- Abstract P4-21-14: A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP (2017) (1)
- Abstract CT215: RELAY, ramucirumab plus erlotinib (RAM+ERL) versus placebo plus erlotinib (PBO+ERL) in previously untreatedEGFRmutation-positive metastatic NSCLC: Next generation sequencing (NGS) results (2020) (1)
- Psychosocial effects of appearance changes due to cancer treatment and needs for information and supportive care in Japanese cancer patients (2020) (1)
- The significance of micro-EGFR T790M mutation on EGFR-TKI efficacy in patients with NSCLC: The WJOG13119L study. (2022) (1)
- Abstract 1193: DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, abrogates the resistance to T-DM1 in HER2-positive gastric cancer: a preclinical study (2017) (1)
- A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904). (2010) (1)
- A phase II study of 3-week scheduling of irinotecan (I) in combination with cisplatin (P) (revised-IP) in patients with stage IIIB or IV non-small cell lung cancer (NSCLC). (2004) (1)
- O1-21-6A PHASE III STUDY OF CDDP, ETOP AND IRINOTECAN VS. TOPOTECAN AS 2ND-LINE CHEMOTHERAPY FOR SENSITIVE RELAPSED SCLC: JCOG0605 (2014) (1)
- RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC (2022) (1)
- FP14.16 Phase 2 Trial of the Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer (WJOG10818L/Alt Trial) (2021) (1)
- Gastroparesis as a significant gastrointestinal adverse event during intensive chemotherapy for solid caner: a case report (2021) (1)
- Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis (West Japan Oncolgy Group 6711L): A Phase II Study (2015) (1)
- The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC (2022) (1)
- Abstract C20: Phase I study of ombrabulin, a vascular disrupting agent (VDA), administered every 3 weeks to Japanese patients with advanced solid tumors. (2011) (1)
- Amyloid Colitis: Successful Treatment with Colchicine Therapy (1998) (1)
- Regression of brain metastases from breast cancer with eribulin: a case report (2013) (1)
- Phase I Dose-escalation and Pharmacokinetic Trial of Lapatinib ( GW 572016 ) , a Selective Oral Dual Inhibitor of ErbB-1 and-2 Tyrosine Kinases , in Japanese Patients with Solid Tumors (2008) (1)
- OA11.02 Randomized Phase 1b/3 Study of Erlotinib plus Ramucirumab in First-Line EGFR Mut + Stage IV NSCLC: Phase 1b Safety Results (2017) (1)
- [Cancer of unknown primary site-current status and future direction]. (2009) (1)
- A randomized phase 3 study of maintenance therapy with S‐1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S‐1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L) (2020) (1)
- [Prognosis of small cell lung cancer with ipsilateral pleural effusion]. (1992) (1)
- A randomized phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small cell lung cancer (JCOG1201/TORG1528). (2021) (1)
- Tolerability and antitumor activity of ASP8273 in TKI-naive Japanese subjects with EGFR mutation–positive non-small cell lung cancer. (2017) (1)
- RELAY study of erlotinib (ERL) + ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts). (2020) (1)
- Amplification of OCT4-Pseudogene POU5F1B is a Poor Prognostic Factor in Gastric Cancer (2012) (1)
- The different effects of recombinant human tumor necrosis factor on rat fibrosarcoma sublines (2004) (1)
- Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma (2022) (1)
- Abstract 5169: Novel target molecules for treatment of cancer of unknown primary (2018) (1)
- Prognostic impact of geriatric assessment in elderly patients with non-small cell lung cancer: an integrated analysis of two randomized phase III trials (JCOG1115-A). (2021) (1)
- Yolk Sac Tumor in a Recurrence of Colonic Adenocarcinoma With Shared Mutations in APC and TP53 Genes: A Case Report (2022) (1)
- Pharmacokinetics (PK) and Safety of Tesetaxel, a Novel Oral Taxane, in Japanese Patients (PTS) with Advanced Solid Tumors (2012) (1)
- P2.06-021 Efficacy and Safety of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment in Subjects with EGFRMut+ NSCLC: Topic: Phase III (2017) (1)
- Double masking study of Ubenimex (bestatin) on squamous cell lung cancer (1991) (1)
- Preclinical Development Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib ( PF-02341066 ) in Gastric Cancer Positive for MET Ampli fi cation (2012) (1)
- RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship (2022) (1)
- Prognostic factors in post-surgical recurrence of lung cancer (2000) (1)
- Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non–small cell lung cancer (2013) (1)
- Clinical development of EGFR-tyrosine kinase inhibitors in Japan (2006) (1)
- Challenges in lung cancer multidisciplinary collaboration experienced by specialists in four countries. (2021) (1)
- Abstract 1231: Differential roles of trans-phophorylated EGFR, HER2, HER3 and RET as heterodimerization partenrs of MET in lung cancer with MET amplification (2012) (1)
- Perspectives in drug development for cancer therapy in Asia. (2013) (1)
- Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed (2019) (1)
- Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405) (2022) (1)
- MO4-5 A multicenter retrospective study of Oncomine Dx Target Test multi-CDx system for genetic profiling of NSCLC: WJOG13019L (2021) (1)
- [The survey for anti-emetic guideline by using questioner]. (2015) (1)
- 1209P RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+NSCLC): Association between TP53 status and clinical outcome (2021) (1)
- A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group Trial (WJTOG) 2905. (2012) (1)
- [Phase I-II study of recombinant interleukin-2]. (1987) (1)
- MO36-4 A multi-institutional, single-arm phase II study of pembrolizumab plus amrubicin in relapsed small cell lung cancer (2021) (1)
- P3.02a-005 The Association between the Percentage of Anaplastic Lymphoma Kinase(ALK)-Positive Cells and Efficacy of ALK Inhibitor: Topic: ALK Biomarkers (2017) (1)
- Abstract 3858: Synergistic antitumor effects of combination therapy with S-1 and HER2 targeting agents in gastric cancer with HER2 amplification (2010) (1)
- Abstract 3893: Overexpression of FOXQ1 is important factor in tumorigenicity and tumor growth (2010) (1)
- A Novel Mass Spectrometry-Based Assay for Diagnosis of EML4-ALK-Positive Non-Small-Cell Lung Cancer (2012) (1)
- [Management of side effects with platinum doublet chemotherapy used for treatment of non-small cell lung cancer]. (2015) (1)
- Abstract 3993: A microarray-based gene expression analysis identified diagnostic biomarkers for unknown primary cancer (2014) (1)
- OA 05.03 Clinical Activity of ASP8273 in Asian Non-Small Cell Lung Cancer Patients with EGFR Activating and T790M Mutations (2017) (1)
- Large Cell Neuroendocrine Carcinoma of the Mediastinum with -Fetoprotein Production (2008) (1)
- Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in the Japanese population. (2020) (1)
- Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced NSCLC. (2021) (1)
- Predictive impact of complete molecular response in plasma: A phase II, liquid biopsy study in EGFR mutated NSCLC patients treated with afatinib (WJOG 8114LTR). (2017) (1)
- Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy? (2020) (1)
- A phase I/II study of pemetrexed plus cisplatin in Japanese patients with malignant pleural mesothelioma (2007) (1)
- A first attempt to establish a definition of oligometastatic non-small cell lung cancer by a European consensus group. (2019) (1)
- Abstract 1731: TAK-701, a humanized monoclonal antibody to HGF, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with anEGFRmutation (2011) (1)
- Randomized phase III study comparing etoposide and cisplatin (EP) with irinotecan and cisplatin (IP) following EP plus concurrent accelerated hyperfractionated thoracic radiotherapy (EP/AHTRT) for the treatment of limited-stage small-cell lung cancer (LD-SCLC): JCOG0202. (2012) (1)
- MO4-1 EGFR inhibitor upregulates HER3 expression and enhances the efficacy of anti-HER3 antibody drug conjugate U3-1402 (2021) (1)
- Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer. (2007) (1)
- A phase II study of osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer harboring EGFR mutations: The OCEAN study (LOGIK 1603/WJOG 9116L). (2020) (1)
- Final overall survival results of a randomized phase III trial comparing weekly docetaxel plus cisplatin (DP) with 3-weekly docetaxel (D) monotherapy in elderly patients (pts) with advanced non-small-cell lung cancer (NSCLC): intergroup trial JCOG0803/WJOG4307L. (2015) (1)
- The efficacy of the ALK inhibitor crizotinib as compared with standard chemo- therapy as first-line treatment for advanced ALK-positive non–small-cell lung can- (2019) (0)
- B-42 Expression of Glutathione S-Transferase πGene in Human Lung Cancer Cell Lines (1991) (0)
- [Result of Clinical Trials of Ceritinib in Patients with ALK-Rearranged Non-Small-Cell Lung Cancer and Management of the Adverse Events]. (2018) (0)
- A phase I/I b study of GSK1120212 (trametinib) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. (2013) (0)
- Relationship between checkpoint molecule B7-H3 and refractoriness to anti-PD-1 therapy in non-small cell lung cancer. (2018) (0)
- OA03.07 Pembrolizumab for Advanced Mesothelioma: Results from the Phase 2 KEYNOTE-158 Study (2021) (0)
- Phase II study of amrubicin (AMR) in patients (pts) with non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy: WJTOG0401. (2009) (0)
- Erratum to: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer (2013) (0)
- Efficacy of Crizotinib after Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged Non–Small Cell Lung Cancer: Case Report (2023) (0)
- SPS-9Safety Profile of Nivolumab in Japanese NSCLC Pts: Interim Results from Post-marketing All-Case Surveillance in Japan (2017) (0)
- Phase I dose finding study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, alone or in combination with paclitaxel in Japanese patients. (2013) (0)
- Augmentation of colony formation of cultured cell lines by pleural effusion from patients with lung cancer. (1988) (0)
- Abstract A67: Phase I study of HER3 targeted antibody patritumab (U3-1287) in combination with erlotinib in Japanese patients with non-small cell lung cancer (NSCLC). (2013) (0)
- P2.08-007 Listen Advocate Voice - Web-Survey for the Japanese Model of Lung Cancer Advocacy by Society: Topic: Patient’s Voice, Patient’s Information (2017) (0)
- Abstract 1844: Novel HER3 neutralizing antibody, patritumab abrogates cetuximab resistance mediated by a heregulin-autocrine loop in colorectal cancer (2014) (0)
- [Gefitinib in non-small cell lung cancer]. (2004) (0)
- I Safety , Pharmacokinetic , and Biomarker Study of F 1120 , an Oral Triple Tyrosine Kinase Inhibitor in Ther ients with Advanced Solid Tumors (2010) (0)
- Pharmacokinetics of amrubicin in lung cancer patients with impaired hepatic function (2016) (0)
- 1247 Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in Japanese patients with solid tumors (2009) (0)
- [International clinical trials for a medical oncologist in Japan]. (2007) (0)
- Cancer Cell Lines : Relation to DNA Damage and Repair-Diamminedichloroplatinum ( II ) in Human Non-Small Cell Lung cis Decreased Accumulation as a Mechanism of Resistance to Updated (2006) (0)
- TREATMENT PERIODS AND SUBJECTS IN THE COHORT AND NUMBER OF CASES AND CONTROLS IN THE NESTED CASE-CONTROL (2008) (0)
- Is EGF receptor–tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option? (2013) (0)
- P-560 Phase I-II study of amrubicin and cisplatin as first-line treatment in patients with extensive stage small cell lung cancer (ED-SCLC) (2003) (0)
- WS1. the expansion of surgical indication in gastric colorectal cancer drug therapy (2012) (0)
- [Pilot study of dose intensive weekly chemotherapy followed by cisplatin plus etoposide with concurrent thoracic irradiation for limited-disease small-cell lung cancer. West Japan Thoracic Oncology Group]. (2000) (0)
- Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (2022) (0)
- Patients' Preferences for Attributes of Molecular Targeting Therapies for Advanced Non-Small Cell Lung Cancer with EGFR Mutations in Japan-A Discrete-Choice Experiment. (2022) (0)
- MO29-5 RELAY+: Exploratory study of RAM+GEF in untreated patients with EGFR M+ NSCLC: Updates on efficacy, safety and biomarker (2021) (0)
- Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (2022) (0)
- A new antitumor antibiotic FR66973: clonogenic in vitro assessment of activity against human non-small cell lung carcinoma (1987) (0)
- Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer (2019) (0)
- O3-12-3SURVIVAL OUTCOME ASSESSED ACCORDING TO TUMOR RESPONSE AND SHRINKAGE PATTERN IN EGFR(+)NSCLC TREATED WITH EGFR-TKI (2014) (0)
- Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis. (2022) (0)
- Phase I and Pharmacokinetics Trial of BNP7787 in Patients Receiving Cisplatin and Paclitaxel (2002) (0)
- AUC finding study of daily carboplatin administration combined with concurrent thoracic radiotherapy for elderly non-small cell lung cancer patients (2001) (0)
- 1361TiP Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02) (2021) (0)
- PS02.112: A RETROSPECTIVE STUDY OF NEOADJUVANT 5-FU, DOCETAXEL, AND NEDAPLATIN (UDON) COMBINATION CHEMOTHERAPY FOR ADVANCED ESOPHAGEAL CANCER (2018) (0)
- Prognostic Factors Of Pneumonia In The Elderly Aged Over 80 Years (2011) (0)
- Measurement of cytokeratin 19 fragments as a new lung cancer marker by CYFRA 21-1 enzyme immunoassay (1994) (0)
- P76.67 Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050 (2021) (0)
- Immune-Related Adverse Events-A Novel Prediction of Nivolumab Efficacy?-Reply. (2018) (0)
- Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L) (2021) (0)
- Corrigendum to "Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer" [Lung Cancer 121 (July) (2018) Pages 37-40]. (2019) (0)
- 93 Are the Human Lung Cancer Cell Lines Useful to Screen Effective Agents against Lung Cancer (1988) (0)
- [Efforts of medical technologists for cancer patients--a questionnaire survey following a lecture meeting: "cancer treatment and clinical examinations" for cancer patients and their families]. (2010) (0)
- O1-7-1PHASE I TRIAL OF ERIBULIN/S-1 COMBINATION THERAPY FOR ADVANCED/RECURRENT BREAST CANCER (2014) (0)
- [The Achievements for"7-University Joint Project of Training Plan for Oncology Professionals]. (2022) (0)
- Differences in cellular proteins between high and low metastatic potential sublines from the methylcholanthrene-induced rat fibrosarcoma cell line. (1992) (0)
- MO44-4 Phase II study of nivolumab rechallenge in advanced NSCLC pts who responded to prior anti-PD-1/L1 inhibitors; WJOG 9616L (2022) (0)
- ISS1-2-1Updates on PFS and safety results of a Phase I / II study (AF-001JP) of alectinib in ALK-rearranged advanced NSCLC (2015) (0)
- A phase II study on the efficacy of Nivolumab in Japanese patients with cancer of unknown primary (CUP) (NivoCUP). (2018) (0)
- O3-15-3HEREGULIN AS A BIOMARKER FOR ANTI-HER3 ANTIBODY PATRITUMAB COMBINED WITH ERLOTINIB IN NON-SMALL CELL LUNG CANCER (2014) (0)
- Abstract P3-10-07: Phase I trial of eribulin in combination with S-1 for advanced and recurrent breast cancer patients (2015) (0)
- Vinorelbine Plus Cisplatin Versus Gefitinib in Resected Non-Small-Cell Lung Cancer Haboring Activating EGFR Mutation (WJOG6410L) (2012) (0)
- [A mechanism of cisplatin resistance in a cisplatin resistant lung cancer cell line]. (1990) (0)
- Next-generation sequencing–based clinical testing for lung cancer in Japan (2017) (0)
- P2-2-2The safety and efficacy profiling of T-DM1 treatments of metastatic breast cancer patients (2015) (0)
- Reply to Binghao Zhao et al. (2022) (0)
- Reply to A.-M. Conway et al. (2019) (0)
- O1-9-2TUMOR GENOMIC PROFILING OF NSCLC FROM THE PHASE III TRIAL OF FIRST-LINE S-1/CBDCA VERSUS PACLITAXEL/CBDCA (WJOG6611LTR) (2014) (0)
- Attention Study: Asian Trial of Tivantinib Plus Erlotinib Versus Erlotinib for NSCLC without EGFR Mutation; a Phase 3 Trial with a Personalized Dose Setting Based on Pretreatment Test for CYP2C19 Polymorphism (2012) (0)
- The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050. (2020) (0)
- P-131 Expression of tumor associated antigens (MAGE, NY-ESO-1, OY-TES-1) in pulmonary carcinoma (2003) (0)
- Tokuda Akihiro Tomida Shinya Toyokuni Hitoshi Tsuda Shoichiro Tsugane Tatsuhiko Tsunoda Heiichiro Udono Koji Ueda Yoshimasa Uehara Hiroo Ueno Kazuo Umezawa Toshikazu Ushijima Toshihiko Wakabayashi Kenji Wakai Tetsuro Watabe (2016) (0)
- Retraction (2021) (0)
- A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L (2018) (0)
- Considering adequate amount of palbociclib due to neutropenia in 28 Japanese patients with advanced breast cancer - real world data of single institution (2019) (0)
- P-0118 Chemotherapy with Cpt-11 After Gemcitabine Failure in Patients with Advanced Pancreatic Cancer (2012) (0)
- A Phase I Study of Chemoradiotherapy with Use of Three-dimensional Conformal Radiotherapy (3D-CRT) and Accelerated Hyperfractionation (AHF) for Unresectable Non-small Cell Lung Cancer (NSCLC): WJOG3305 (2010) (0)
- O3-12-4INTERNATIONAL SURVEY FOR SMOKING PREVALENCE AND SPONTANEOUS AWARENESS OF THE SYMPTMOS OF LUNG CANCER (2014) (0)
- Phase I study of YM155, selective survivin suppressant in combination with elrotnib in patients with EGFR-mutant advanced non-small cell lung cancer. (2016) (0)
- Efficacy and Safety ofTwo Doses of Pemetrexed Supplemented with Folic Acid andVitamin B 12 in PreviouslyTreated Patients with Non-Small Cell Lung Cancer (2008) (0)
- 9105 Phase III study of concurrent chemoradiotherapy followed by surgery (S) vs. chemotherapy (C) followed by S for stage IIIA (pN2) non-small cell lung cancer (NSCLC): results of prematurely terminated trial, WJTOG9903 (2009) (0)
- Phase I Study of Combination Therapy with Interleukin 2 and ^-Interferon in Patients with Advanced Malignancy1 (2006) (0)
- 9072 Phase II study of amrubicin (AMR) in patients (pts) with non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy, a further analysis on adverse effect: WJTOG0401 (2009) (0)
- In Reply. (2018) (0)
- Gene expression and mutation profiling for cancer of unknown primary. (2017) (0)
- BiomarkerAnalysesandFinalOverallSurvivalResultsFroma PhaseIII,Randomized,Open-Label,First-LineStudyofGefitinib VersusCarboplatin/PaclitaxelinClinicallySelectedPatientsWith AdvancedNon-Small-CellLungCancerinAsia(IPASS) (2011) (0)
- P-0117 Second-Line Chemotherapy with S-1 after Cisplatin and Gemcitabine Failure in Patients with Advanced Biliary Tract Cancer (2012) (0)
- Capecitabine plus Cisplatin treatment for advanced gastric cancer in a patient with hepatic impairment secondary to metastases. (2012) (0)
- O19-4 Outcomes in Japanese patients with TMB-high and non-TMB-high solid tumors treated with pembrolizumab: KEYNOTE-158 (2022) (0)
- Association of thymidylate synthase (TS) expression with response to S-1 plus carboplatin (CBDCA) in non-small cell lung cancer (NSCLC) patients (pts). (2010) (0)
- MA06.11 Phase II Study of Nimotuzumab + Concurrent Chemoradiotherapy (CRT) for Stage III Non-Small Cell Lung Cancer (NSCLC): 5-Year Follow-Up Results (2017) (0)
- OS1. gastric cancer (2012) (0)
- 556 Pilot combination phase II study of Carboplatin (CBDCA) and Etoposide (VP-16) for small cell lung cancer. (1988) (0)
- O3–096BIOMARKER ANALYSIS OF WJOG4107 (A RANDOMIZED PHASE II TRIAL OF ADJUVANT CHEMOTHERAPY WITH S-1 VS CDDP + S-1 IN NSCLC) (2013) (0)
- Potential research and clinical utility of liquid biopsy with CAPP seq. (2018) (0)
- Carboplatin and Irinotecan (CI) vs. Carboplatin and Etoposide (CE) for the Treatment of Extended-Stage Small-Cell Lung Cancer in an Elderly Population: A Phase II/III Randomized Control Trial (2023) (0)
- O3-9-4CLINICAL BENEFIT OF CONTINUED THERAPY WITH CRIZOTINIB BEYOND INITIAL DISEASE PROGRESSION IN ADVANCED ALK POSITIVE NSCLC (2014) (0)
- Abstract 1095: Short Poly A sequence in HGF promoter region is involved in overexpression of HGF in cancer cells (2011) (0)
- 723 POSTER A phase I dose-escalation study of RAD001 administered daily to Japanese patients with advanced solid tumors (2007) (0)
- [Current problems of early phase clinical trials for new anticancer agents in Japan]. (2000) (0)
- MO37-6 Longitudinal disease monitoring with ctDNA during osimertinib treatment in EGFR T790M positive NSCLC patients (WJOG8815L) (2021) (0)
- Chemotherapy versus best supportive care in advanced lung cancer and idiopathic interstitial pneumonias: A retrospective multi-centre cohort study. (2022) (0)
- Effects of Dose Modifications on Safety and Efficacy of Dacomitinib for EGFR+ NSCLC in ARCHER 1050 Japanese Subset (2019) (0)
- Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study (2022) (0)
- RELAY: Global Ph3 study of erlotinib + ramucirumab or placebo in metastatic NSCLC with EGFR mutation - East Asian subset (2019) (0)
- O3-1 A phase II study on the efficacy of nivolumab in patients with cancer of unknown primary (CUP) (NivoCUP) (2021) (0)
- Relationship between EGFR protein expression, EGFR gene amplification, EGFR gene mutations and gefitinib sensitivity in human non-small cell lung cancer cell lines (2006) (0)
- Overall survival (OS) of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns of 1,660 Japanese patients (pts). (2016) (0)
- P2-311: Randomized phase II study of carboplatin and paclitaxel (CP) versus gemcitabine and vinorelbine (GV) in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): Results of a West Japan Thoracic Oncology Group study (WJTOG0004) (2007) (0)
- Incorrect Email Address for Corresponding Author. (2018) (0)
- A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. (2023) (0)
- O1-9-1ARCHER 1050: first-line dacomitinib vs gefitinib for advanced NSCLC in patients with EGFR activating mutation(s) (2015) (0)
- Randomized phase 3 study of maintenance therapy with S-1 plus best supportive care (BSC) versus BSC alone after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell lung carcinoma (WJOG7512L). (2019) (0)
- P2-1-55Immune-related response kinetics in patient with melanoma receiving nivolumab, programmed cell death 1 (PD-1) inhibitor (2015) (0)
- E-22 Establishment of Tumor Cell Lines as An Independent Prognostic Factor in Small Cell Lung Cancer (SCLC) (1991) (0)
- [Neoadjuvant Triplet Combination Chemotherapy(UDON Therapy)in Esophageal Cancer Patients with Impaired Renal Function-A Retrospective Study]. (2019) (0)
- Estimated risks of recurrence and mortality in lung cancer: comprehensive analysis by a population-based study (2017) (0)
- Successful treatment of a case of hormone receptor–positive metastatic extramammary Paget disease with tamoxifen (2021) (0)
- [Effects of recombinant human colony stimulating factor (rh-CSFs) on colony formation of lung cancer cell lines]. (1989) (0)
- Abstract 4446: Activation of HER Family signaling as a mechanism of acquired resistance to ALK Inhibitors in EML4-ALK-positive Non-Small Cell Lung Cancer. (2013) (0)
- Transcriptional expression of Bcl-2 as predictive of response to neoadjuvant chemotherapy with trastuzumab in HER2-positive ER-positive breast cancer patients. (2014) (0)
- Advances in Brief Point Mutations of the Topoisomerase IIÂ « Gene in Patients with Small Cell Lung Cancer Treated with Etoposide 1 (2006) (0)
- Abstract CT078: A prospective biomarker study using digital PCR method in EGFR-mutated, advanced lung adenocarcinoma patients treated with afatinib (West Japan Oncology Group 8114LTR) (2016) (0)
- Postprogression Survival for Advanced NSCLC (2012) (0)
- 557 Characterization of the p16 status of the tumor cell lines in the NCl drug screen panel identifies small molecule inhibitors of CDK4 (1997) (0)
- 9104 Randomized phase III study of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (CTR) for patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): West Japan Thoracic On (2009) (0)
- P50.01 RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19-del Variants (2021) (0)
- Abstract 2173: A multi-institutional prospective biomarker study of durvalumab after concurrent chemoradiation therapy in patients with unresectable stage III non-small cell lung cancer (WJOG11518L/SUBMARINE) (2023) (0)
- Brigatinib in Japanese patients (pts) with ALK+ NSCLC: Final results from the phase 2 J-ALTA trial. (2022) (0)
- SPS-9Safety Profile of Nivolumab in Japanese NSCLC Pts: Interim Results from Post-marketing All-Case Surveillance in Japan (2017) (0)
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer (2022) (0)
- Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS) (2022) (0)
- A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L) (2020) (0)
- Cyclin dependent kinase (cdk) 4 inhibitors and their use for the treatment of cancer (1998) (0)
- P-44 Cumulative toxicity of long-term docetaxel administration in patients with solid tumors (2003) (0)
- Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society (2022) (0)
- [Future direction of medical oncology in Japan]. (2012) (0)
- O2-3-5Bevacizumab beyond disease progression in advanced non-squamous NSCLC (WJOG 5910L): a randomized phase II trial (2015) (0)
- Cell cycle regulation and radiosensitization of TZT-1027, a novel antimicrotubule agent (2006) (0)
- Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer (2019) (0)
- Tyrosine phosphoproteomics identified both co-drivers and co-targeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer RUNNING TITLE: Phosphoproteomics of EGFR-TKI resistance (2014) (0)
- O1-8-3Phase II study of erlotinib + onartuzumab as first-line treatment for patients with MET-positive and EGFR-mutant NSCLC (2015) (0)
- Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study) (2017) (0)
- Marked response to both S-1 and pemetrexed in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinoma (2012) (0)
- P2.03a-009 Clinical Outcome of Node-Negative Oligometastatic Non-Small Cell Lung Cancer: Topic: Clinical Trials (2017) (0)
- Incidence of interstitial lung disease (ILD) and risk factors for developing ILD: A final analysis of a large-scale erlotinib Japanese surveillance study in non-small-cell lung cancer (NSCLC) (2013) (0)
- Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial. (2023) (0)
- Abstract. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are efficacious drugs for non‐small cell lung cancers (NSCLCs) with EGFR‐activating mutations. Afatinib, a second-generation EGFR-TKI and osimertinib, a third-generation EGFR-TKI, are both standard therapies for patien (2018) (0)
- Abstract 424: Amplification ofOCT4-pseudogenePOU5F1Bis a poor prognostic factor in gastric cancer (2012) (0)
- Abstract P3-13-08: A phase I study of weekly nab-paclitaxel in combination with S-1 in patients with metastatic breast cancer (2013) (0)
- A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer (2015) (0)
- 65 Seven Small Cell Lung Cancer (SCLC) Cell Lines established from Bronchofiberscope Biopsies (1991) (0)
- Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402). (2022) (0)
- Abstract. Patients with non-small cell lung cancer (NSCLC) with echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangements (2014) (0)
- Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, FTD/TPI, with Ramucirumab Murine Version DC101 in a Mouse Syngeneic Cancer Transplantation Model (2020) (0)
- Pilot Study of Docetaxel for Cisplatin- or Irinotecan-Refractory Non-Small Cell Lung Cancer. (2000) (0)
- Abstract 3733: Heregulin as a novel resistant factor for cetuximab (2010) (0)
- Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study (2023) (0)
- Pooled safety analysis of EGFR-TKI therapy in patients with EGFR-mutated non-small cell lung cancer. (2014) (0)
- Abstract 1736: Src inhibitor dasatinib enhances anti-tumor activity of irreversible or T790M-selective epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer cells with T790M gate-keeper mutation (2011) (0)
- O11-3 Phase 2 trial of atezolizumab with bevacizumab for patients with PD-L1 high non-Sq NSCLC (WJOG10718L/At Be Study) (2021) (0)
- O1-13-4Integrative algorithm to determine the metastatic carcinoma tissue of origin using next generation sequencing (NGS) (2015) (0)
- The impact of sequential therapy of crizotinib followed by alectinib: Real-world data analysis of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L). (2019) (0)
- P3.02b-086 ASP8273 Tolerability and Antitumor Activity in TKI-Naïve Japanese Subjects with EGFRmut+ NSCLC: Preliminary Results: Topic: EGFR Clinical (2017) (0)
- A Case of Glioblastoma Multiforme with Hematogenous Metastases to the Pleura (2015) (0)
- Exploratory analysis of JFCM: Predictive value of rash, EGFR expression, and EGFR copy for necitumumab in squamous NSCLC (2019) (0)
- Postprogression Survival for First-Line Chemotherapy in Patients with Advanced Gastric Cancer (2012) (0)
- A long-term result by hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small cell lung cancer (LD-SCLC): a retrospective analysis in a single institution: P1-236 (2007) (0)
- IS6-5PHASE I STUDY OF YM155, SELECTIVE SURVIVIN SUPPRESSANT PLUS ERLOTINIB IN PATIENTS WITH EGFR-MUTANT ADVANCED NSCLC (2014) (0)
- Population PK/PD Analysis of Necitumumab: Dose justification for Squamous Cell Lung Cancer (SqCLC) Patients in Japan (2019) (0)
- Amplification MET ( PF-02341066 ) in Gastric Cancer Positive for Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (2013) (0)
- Abstract 2939: Heregulin-induced resistance against HER2-targeted therapies in HER2 positive breast and gastric cancer in vitro and in vivo (2016) (0)
- O6-3 The significance of ultra-low EGFR T790M mutations on EGFR-TKI efficacy in patients with NSCLC -the WJOG13119L study (2022) (0)
- Development of PD-1 Inhibition in Cancer Therapy: Dramatic Advances for Medical Oncology (2019) (0)
- Correction: Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma (2023) (0)
- Biomarker analysis of WJOG4107, a randomized phase II trial of adjuvant chemotherapy with S-1 versus CDDP+S-1 for resected stage II-IIIA non-small cell lung cancer (NSCLC). (2013) (0)
- MO29-2 Osimertinib for RT-naïve CNS metastasis of EGFRm NSCLC: pll OCEAN study (LOGIK 1603/WJOG 9116L), part of T790M cohort (2021) (0)
- [A Case of Advanced Esophageal Cancer Successfully Treated with Neoadjuvant Chemotherapy Containing 5-FU, Docetaxel. and Nedaplatin Combination Therapy]. (2018) (0)
- Response to "Letter to the Editor" From David Y. Mak et al. (2023) (0)
- Phase I/II study of nab-paclitaxel (nab-P) with cisplatin (C) and thoracic radiation (TRT) in patients with locally advanced NSCLC: Safety results of phase I part. (2016) (0)
- Contribution of MMP14-expressing cancer-associated fibroblasts in the tumor immune microenvironment to progression of colorectal cancer (2022) (0)
- Treatment for small cell lung cancer--present status and future prospects. (1988) (0)
- Practical Use of Gemcitabine and Cisplatin Combination Therapy as First-Line Treatment for Japanese Patients with Advanced Biliary Tract Cancer (2013) (0)
- [EFFECTIVENESS OF ADD-ON SUBLINGUAL IMMUNOTHERAPY FOR THE TREATMENT OF JAPANESE CEDAR POLLINOSIS-ASSOCIATED ALLERGIC ASTHMA IS IT POSSIBLE TO REDUCE THE DOSE OF INHALED CORTICOSTEROID BY ADDING SUBLINGUAL IMMUNOTHERAPY?] (2021) (0)
- AOJ-5THE COUNTERMEASURE FOR AGING SOCIETY IN JAPAN (2014) (0)
- Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L) (2021) (0)
- 89 Relationship between GST-π Gene Expression and Cisplatin Resistance in Lung Cancer Cells. Natl. Cancer Cent. (1988) (0)
- Cell Lung Cancer Small − Positive Non − Resistance to ALK Inhibitors in EML 4-ALK Activation of HER Family Signaling as a Mechanism of Acquired (2013) (0)
- Abnormality of growth hormone and insulin-like growth factor I axis in advanced cancer patients (2007) (0)
- Multi-Institutio nal R andomized P hase I I T rial o f G efitinib f or Previously T reated P atients W ith A dvanced N on-Small-Cell Lung C ancer (2003) (0)
- P-62 Phase II trial of irinotecan plus cisplatin after cisplatin plus etoposide and concurrent thoracic radiotherapy (TRT) in small cell lung cancer (SCLC) patients with limited disease: West Japan Thoracic Oncology Group 9902 (2003) (0)
- Abstract 2545: Roles of BIM induction and survivin down-regulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification (2011) (0)
- Implementation of clinical sequencing for molecular profiling in patients with advanced cancer. (2021) (0)
- PD3-3-2: A randomized double-blind Phase IIa dose-finding study of vandetanib in Japanese patients with NSCLC (2007) (0)
- MA08.10 Detection of the T790M Mutation of EGFR in Plasma of Advanced NSCLC Patients with Acquired Resistance to EGFR-TKI (WJOG8014LTR) (2017) (0)
- Correction: KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms (2022) (0)
- 134 Correlation between CDDP Resistance and The Expression of Glutathione S-Transferase-π Gene in Ovarian Cancer Cell Lines. (1989) (0)
- Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to ionizing radiation (2005) (0)
- O3-15-2CHRONIC NICOTINE EXPOSURE MEDIATES RESISTANCE TO EGFR-TKI IN EGFR-MUTATED LUNG CANCER VIA EGFR SIGNAL (2014) (0)
- P2.06-037 A Feasibility Study of Concurrent Chemoradiation Followed by Surgery for Pathologically-Proven Clinical IIIA-N2 Non-Small Cell Lung Cancer: Topic: Radiotherapy, TT Fields (2017) (0)
- Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L). (2022) (0)
- Molecular Cancer apeutics cular Medicine in Practice se I Safety , Pharmacokinetic , and Biomarker Study of F 1120 , an Oral Triple Tyrosine Kinase Inhibitor in Ther ients with Advanced Solid Tumors (2010) (0)
- [A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer]. (2011) (0)
- Lines Small Cell Lung Cancer Cell − Survivin Suppressant , in Non Radiosensitizing Effect of YM 155 , a Novel Small-Molecule (2008) (0)
- P1.16-43 Analyses of Long-Term Outcomes and Prognostic Factors in Surgically Resected ALK-Rearranged Lung Adenocarcinoma (2018) (0)
- Phase II study of osimertinib in patients with plasma EGFR T790M positive advanced lung cancer (WJOG8815L/LPS). (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Kazuhiko Nakagawa?
Kazuhiko Nakagawa is affiliated with the following schools:
- Saitama Medical University
- Kyushu University
- Yasuda Women's University
- University of Tokyo
- Fukuoka University
- National Taiwan University
- Osaka University
- Tokyo Medical University
- Kyoto University
- Hokkaido University
- Osaka Metropolitan University
- Kobe University
- Chinese University of Hong Kong
- Institute of Science Tokyo
- Okayama University
- Kindai University
